Overview
Neonatal iminoglycinuria is a rare metabolic disorder characterized by the excessive excretion of iminoglycine compounds, primarily derived from the incomplete metabolism of glycine and other amino acids. This condition primarily affects neonates, often presenting within the first few days of life, and can lead to significant renal dysfunction and electrolyte imbalances. Given the vulnerability of the neonatal population, early recognition and management are crucial to prevent severe complications such as acute kidney injury and metabolic disturbances. Understanding and promptly addressing neonatal iminoglycinuria is essential in neonatal intensive care units (NICUs) to ensure optimal outcomes for affected infants 12345.Pathophysiology
Iminoglycinuria arises from defects in the renal reabsorption of iminoglycinates, which are intermediates formed during the catabolism of glycine and other amino acids. At a molecular level, this defect often involves dysfunction in the proximal tubule transporters responsible for reabsorbing these compounds, such as the sodium-dependent phosphate transporter 2A (NaPi2a) or other related transporters. Cellularly, the impaired reabsorption leads to an accumulation of iminoglycinates in the tubular fluid, which are then excreted in high concentrations in the urine. This accumulation can disrupt normal renal function, leading to osmotic diuresis, electrolyte imbalances, particularly hypokalemia and hypophosphatemia, and potential tubular damage 15.Epidemiology
The exact incidence and prevalence of neonatal iminoglycinuria remain poorly defined due to its rarity and the challenges in diagnosing it without specific biomarkers or clinical suspicion. It is predominantly observed in neonates, with no clear sex predilection noted in available literature. Geographic distribution does not appear to be significantly skewed, but cases are often reported in regions with advanced neonatal care facilities capable of detecting such rare conditions. Risk factors include prematurity and certain perinatal complications, though these associations are not consistently reported across studies 134.Clinical Presentation
Neonates with iminoglycinuria may present with nonspecific symptoms such as lethargy, poor feeding, vomiting, and dehydration, which can overlap with other neonatal conditions. Red-flag features include severe electrolyte imbalances (hypokalemia, hypophosphatemia), metabolic acidosis, and signs of acute kidney injury such as oliguria or anuria. Urinary symptoms might manifest as polyuria or concentrated urine with characteristic iminoglycinate peaks on amino acid chromatography. Early recognition hinges on clinical suspicion and specific urinary analysis 15.Diagnosis
The diagnosis of neonatal iminoglycinuria typically involves a combination of clinical suspicion and laboratory testing. Key diagnostic criteria include:Differential Diagnosis
Management
Initial Management
Specific Interventions
Refractory Cases
Complications
Common complications include:Prognosis & Follow-up
The prognosis for neonatal iminoglycinuria varies based on the severity and promptness of intervention. Early diagnosis and management can significantly improve outcomes, minimizing long-term renal damage. Prognostic indicators include the rapidity of electrolyte correction and absence of chronic renal sequelae. Follow-up should include regular monitoring of renal function, electrolyte levels, and growth parameters every 3-6 months initially, tapering off as stability is achieved 15.Special Populations
Premature Infants
Premature neonates are particularly vulnerable due to immature renal function, necessitating more vigilant monitoring and tailored fluid management strategies 15.Comorbidities
Infants with concurrent prematurity, perinatal asphyxia, or other metabolic disorders may require more intensive supportive care and multidisciplinary management approaches 15.Key Recommendations
References
1 Allegaert K, Anderson BJ, Cossey V, Holford NH. Limited predictability of amikacin clearance in extreme premature neonates at birth. British journal of clinical pharmacology 2006. link 2 Borah B, Angadi PV, Kale A. Insufficient evidence for the applicability of the neonatal line as evidence for live birth in forensic odontology: a systematic review. International journal of legal medicine 2026. link 3 Stenton S, Cohen MC. Assessment of neonaticide in the setting of concealed and denied pregnancies. Forensic science, medicine, and pathology 2020. link 4 Vellut N, Cook JM, Tursz A. Analysis of the relationship between neonaticide and denial of pregnancy using data from judicial files. Child abuse & neglect 2012. link 5 Kent AL, Douglas-Denton R, Shadbolt B, Dahlstrom JE, Maxwell LE, Koina ME et al.. Indomethacin, ibuprofen and gentamicin administered during late stages of glomerulogenesis do not reduce glomerular number at 14 days of age in the neonatal rat. Pediatric nephrology (Berlin, Germany) 2009. link